The clinicaltrials.gov site was updated on Nov. 19 for Ziopharm's trial with Bristol-Myers' Nivolumab (Opdivo), A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102:
1) Recruitment status changed from "Recruiting" to "Active, Not Recruiting"
2) Patients enrolled changed from "18 (Anticipated)" to "21 (Actual)"
3) A new trial site was added: University of Minnesota.
SNO has just started in Phoenix and Ziopharm is presenting tomorrow and Saturday... At Jefferies this week, as you all know, Dr. Cooper said of the IL-12 platform, "We are really ideally positioned ... to improve checkpoint inhibitors." (Around the 23:45 mark). He made a separate reference to "really encouraging survival data." As others have mentioned, we have to believe that players in checkpoint inhibitor space are watching very closely.